FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293100372> ?p ?o ?g. }

• W4293100372 endingPage "604" @default.
• W4293100372 startingPage "592" @default.
• W4293100372 abstract "Antenatal betamethasone is recommended before preterm delivery to accelerate fetal lung maturation. However, reports of growth and neurodevelopmental dose-related side-effects suggest that the current dose (12 mg plus 12 mg, 24 h apart) might be too high. We therefore investigated whether a half dose would be non-inferior to the current full dose for preventing respiratory distress syndrome.We designed a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial in 37 level 3 referral perinatal centres in France. Eligible participants were pregnant women aged 18 years or older with a singleton fetus at risk of preterm delivery and already treated with the first injection of antenatal betamethasone (11·4 mg) before 32 weeks' gestation. We used a computer-generated code producing permuted blocks of varying sizes to randomly assign (1:1) women to receive either a placebo (half-dose group) or a second 11·4 mg betamethasone injection (full-dose group) 24 h later. Randomisation was stratified by gestational age (before or after 28 weeks). Participants, clinicians, and study staff were masked to the treatment allocation. The primary outcome was the need for exogenous intratracheal surfactant within 48 h after birth. Non-inferiority would be shown if the higher limit of the 95% CI for the between-group difference between the half-dose and full-dose groups in the primary endpoint was less than 4 percentage points (corresponding to a maximum relative risk of 1·20). Four interim analyses monitoring the primary and the secondary safety outcomes were done during the study period, using a sequential data analysis method that provided futility and non-inferiority stopping rules and checked for type I and II errors. Interim analyses were done in the intention-to-treat population. This trial was registered with ClinicalTrials.gov, NCT02897076.Between Jan 2, 2017, and Oct 9, 2019, 3244 women were randomly assigned to the half-dose (n=1620 [49·9%]) or the full-dose group (n=1624 [50·1%]); 48 women withdrew consent, 30 fetuses were stillborn, 16 neonates were lost to follow-up, and 9 neonates died before evaluation, so that 3141 neonates remained for analysis. In the intention-to-treat analysis, the primary outcome occurred in 313 (20·0%) of 1567 neonates in the half-dose group and 276 (17·5%) of 1574 neonates in the full-dose group (risk difference 2·4%, 95% CI -0·3 to 5·2); thus non-inferiority was not shown. The per-protocol analysis also did not show non-inferiority (risk difference 2·2%, 95% CI -0·6 to 5·1). No between-group differences appeared in the rates of neonatal death, grade 3-4 intraventricular haemorrhage, stage ≥2 necrotising enterocolitis, severe retinopathy of prematurity, or bronchopulmonary dysplasia.Because non-inferiority of the half-dose compared with the full-dose regimen was not shown, our results do not support practice changes towards antenatal betamethasone dose reduction.French Ministry of Health." @default.
• W4293100372 created "2022-08-26" @default.
• W4293100372 creator A5001617072 @default.
• W4293100372 creator A5002344370 @default.
• W4293100372 creator A5003225431 @default.
• W4293100372 creator A5007049469 @default.
• W4293100372 creator A5010022910 @default.
• W4293100372 creator A5013539858 @default.
• W4293100372 creator A5016904185 @default.
• W4293100372 creator A5023598963 @default.
• W4293100372 creator A5026637793 @default.
• W4293100372 creator A5030972132 @default.
• W4293100372 creator A5033834530 @default.
• W4293100372 creator A5034227885 @default.
• W4293100372 creator A5035681856 @default.
• W4293100372 creator A5036577995 @default.
• W4293100372 creator A5038334310 @default.
• W4293100372 creator A5040760838 @default.
• W4293100372 creator A5051404601 @default.
• W4293100372 creator A5055431095 @default.
• W4293100372 creator A5055884134 @default.
• W4293100372 creator A5058430972 @default.
• W4293100372 creator A5059256161 @default.
• W4293100372 creator A5059769437 @default.
• W4293100372 creator A5079238324 @default.
• W4293100372 creator A5082513352 @default.
• W4293100372 creator A5090263108 @default.
• W4293100372 creator A5090542282 @default.
• W4293100372 creator A5090687526 @default.
• W4293100372 creator A5091161757 @default.
• W4293100372 creator A5091332488 @default.
• W4293100372 creator A5091774225 @default.
• W4293100372 date "2022-08-01" @default.
• W4293100372 modified "2023-10-18" @default.
• W4293100372 title "Neonatal outcomes for women at risk of preterm delivery given half dose versus full dose of antenatal betamethasone: a randomised, multicentre, double-blind, placebo-controlled, non-inferiority trial" @default.
• W4293100372 cites W1878673941 @default.
• W4293100372 cites W1902039366 @default.
• W4293100372 cites W1969728574 @default.
• W4293100372 cites W1985330142 @default.
• W4293100372 cites W1998136841 @default.
• W4293100372 cites W2002519037 @default.
• W4293100372 cites W2014668126 @default.
• W4293100372 cites W2025905907 @default.
• W4293100372 cites W2041013321 @default.
• W4293100372 cites W2064210729 @default.
• W4293100372 cites W2087641300 @default.
• W4293100372 cites W2113902103 @default.
• W4293100372 cites W2129127301 @default.
• W4293100372 cites W2168233879 @default.
• W4293100372 cites W2170106900 @default.
• W4293100372 cites W2321364247 @default.
• W4293100372 cites W2321418212 @default.
• W4293100372 cites W2517077962 @default.
• W4293100372 cites W2521749444 @default.
• W4293100372 cites W2566914768 @default.
• W4293100372 cites W2767794932 @default.
• W4293100372 cites W2944713196 @default.
• W4293100372 cites W2946964653 @default.
• W4293100372 cites W2974342524 @default.
• W4293100372 cites W3027678838 @default.
• W4293100372 cites W3105796402 @default.
• W4293100372 cites W3202347426 @default.
• W4293100372 cites W4213387885 @default.
• W4293100372 cites W4247325209 @default.
• W4293100372 cites W4361868709 @default.
• W4293100372 doi "https://doi.org/10.1016/s0140-6736(22)01535-5" @default.
• W4293100372 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35988568" @default.
• W4293100372 hasPublicationYear "2022" @default.
• W4293100372 type Work @default.
• W4293100372 citedByCount "8" @default.
• W4293100372 countsByYear W42931003722022 @default.
• W4293100372 countsByYear W42931003722023 @default.
• W4293100372 crossrefType "journal-article" @default.
• W4293100372 hasAuthorship W4293100372A5001617072 @default.
• W4293100372 hasAuthorship W4293100372A5002344370 @default.
• W4293100372 hasAuthorship W4293100372A5003225431 @default.
• W4293100372 hasAuthorship W4293100372A5007049469 @default.
• W4293100372 hasAuthorship W4293100372A5010022910 @default.
• W4293100372 hasAuthorship W4293100372A5013539858 @default.
• W4293100372 hasAuthorship W4293100372A5016904185 @default.
• W4293100372 hasAuthorship W4293100372A5023598963 @default.
• W4293100372 hasAuthorship W4293100372A5026637793 @default.
• W4293100372 hasAuthorship W4293100372A5030972132 @default.
• W4293100372 hasAuthorship W4293100372A5033834530 @default.
• W4293100372 hasAuthorship W4293100372A5034227885 @default.
• W4293100372 hasAuthorship W4293100372A5035681856 @default.
• W4293100372 hasAuthorship W4293100372A5036577995 @default.
• W4293100372 hasAuthorship W4293100372A5038334310 @default.
• W4293100372 hasAuthorship W4293100372A5040760838 @default.
• W4293100372 hasAuthorship W4293100372A5051404601 @default.
• W4293100372 hasAuthorship W4293100372A5055431095 @default.
• W4293100372 hasAuthorship W4293100372A5055884134 @default.
• W4293100372 hasAuthorship W4293100372A5058430972 @default.
• W4293100372 hasAuthorship W4293100372A5059256161 @default.
• W4293100372 hasAuthorship W4293100372A5059769437 @default.
• W4293100372 hasAuthorship W4293100372A5079238324 @default.
• W4293100372 hasAuthorship W4293100372A5082513352 @default.
• W4293100372 hasAuthorship W4293100372A5090263108 @default.

• next